论文部分内容阅读
目的:探讨重症肝炎与COX-2的关系,为临床防治重症肝炎提供新的治疗理论和方法。方法:用FH643A-γ测量仪检测50例肝病患者和25例正常对照血清中PGs代谢产物TXB2、6-keto-PGF1α的水平。结果:各组肝病患者血清中TXB2和6-keto-PGF1α的表达水平均明显高于正常人(P<0.001),并且随着病情的好转,T/6-K比值明显下降,但肝病患者各组间细胞因子水平无显著性差异(p>0.05)。结论:检测重症肝炎患者血清TXB2、6-keto-PGF1α的水平和T/6-K比值不仅对揭示肝病发生发展过程有一定的实用价值,而且对监测病情转归和预后有重要临床意义。
Objective: To investigate the relationship between severe hepatitis and COX-2 and to provide new therapies and methods for clinical prevention and treatment of severe hepatitis. Methods: The levels of TXB2, 6-keto-PGF1α in serum of PGs in 50 patients with liver disease and 25 normal controls were detected by FH643A-γ meter. Results: The serum levels of TXB2 and 6-keto-PGF1α in patients with liver disease were significantly higher than those in normal people (P <0.001), and the T / 6-K ratio decreased significantly with the improvement of the disease. However, No significant difference in cytokine levels between groups (p> 0.05). Conclusion: The detection of serum TXB2, 6-keto-PGF1α and T / 6-K ratio in patients with severe hepatitis not only have certain practical value in revealing the development of liver disease, but also have important clinical significance in monitoring the prognosis and prognosis.